GlaxoSmithKline (United Kingdom)
Papers in the tracked journals with an author at GlaxoSmithKline (United Kingdom): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.
Key findings#
- From 2017 to 2026 (so far), authors at GlaxoSmithKline (United Kingdom) took part in 24 papers in the tracked journals, most of them in health economics and policy (15), AI (5) and management (2).
- 7 of them were published in 2025, against 5 in 2017.
- Since 2023, the institutions with the most of these papers were GlaxoSmithKline Research & Development Limited (United Kingdom) (7), GlaxoSmithKline (Belgium) (4) and GlaxoSmithKline (United States) (3).
- The journals publishing most of them were PharmacoEconomics (3), PharmacoEconomics - Open (2) and Nature Machine Intelligence (2).
- The most-cited of them is “Data-driven federated learning in drug discovery with knowledge distillation” (Nature Machine Intelligence, 2025), with 42 citations.
- Since 2023, papers in the tracked journals cited 8 of its papers 13 times; 62% of those links came from papers with a university author and 15% from its own papers.
- Its own papers since 2023 cite archived papers 22 times, 27% of them papers with a company author.
- Across everything OpenAlex indexes, GlaxoSmithKline (United Kingdom) has 18,242 works with 2,910,452 citations (h-index 609).
- The tracked journals hold 23 of its 6,517 works in OpenAlex from 2017 to 2025 (0.4%).
- Its main research topics in OpenAlex are Asthma and respiratory diseases (2,164), Chronic Obstructive Pulmonary Disease (COPD) Research (1,891) and Inhalation and Respiratory Drug Delivery (902).
Papers per year#
20172026 (so far)
| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---|---|---|---|---|---|---|---|---|---|
| Health Economics and Policy | 4 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 2 | 1 |
| AI | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 |
| Management | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Statistics | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| All categories | 5 | 1 | 2 | 0 | 1 | 1 | 3 | 3 | 7 | 1 |
Where the papers come from#
| # | Journal | Papers |
|---|---|---|
| 1 | PharmacoEconomics | 3 |
| 2 | PharmacoEconomics - Open | 2 |
| 3 | Nature Machine Intelligence | 2 |
| 4 | IEEE Transactions on Pattern Analysis and Machine Intelligence | 1 |
| 5 | Expert Systems with Applications | 1 |
| 6 | Patient | 1 |
| 7 | Medical Image Analysis | 1 |
| 8 | BMC Medical Research Methodology | 1 |
| 9 | Health Policy and Technology | 1 |
| 10 | Diagnostic and Prognostic Research | 1 |
| # | Institution | Papers |
|---|---|---|
| 1 | GlaxoSmithKline Research & Development Limited (United Kingdom) | 7 |
| 2 | GlaxoSmithKline (Belgium) | 4 |
| 3 | GlaxoSmithKline (United States) | 3 |
| 4 | Karolinska Institutet | 3 |
| 5 | RTI Health Solutions | 3 |
| 6 | University of Leicester | 3 |
| 7 | Critical Path Institute | 2 |
| 8 | Duchenne UK | 2 |
| 9 | Genentech | 2 |
| # | Country | Papers |
|---|---|---|
| 1 | United Kingdom | 14 |
| 2 | United States | 11 |
| 3 | Belgium | 5 |
| 4 | Sweden | 4 |
| 5 | Germany | 3 |
| 6 | Switzerland | 2 |
| 7 | China | 2 |
| 8 | Denmark | 1 |
| 9 | Spain | 1 |
| 10 | France | 1 |
| # | Keyword | Papers |
|---|---|---|
| 1 | invasive meningococcal disease | 3 |
| 2 | shared decision-making | 3 |
| 3 | Duchenne muscular dystrophy | 2 |
| 4 | MenACWY vaccine | 2 |
| 5 | MenB vaccine | 2 |
| 6 | drug discovery | 2 |
| 7 | natural history model | 2 |
| 8 | pharmaceutical industry collaboration | 2 |
| 9 | public health impact | 2 |
| 10 | quality-adjusted life years | 2 |
Most-cited papers#
Who cites its research#
| # | Institution | Kind | Country | Links |
|---|---|---|---|---|
| 1 | GlaxoSmithKline (Belgium) | Company | Belgium | 3 |
| 2 | GlaxoSmithKline (United States) | Company | United States | 3 |
| 3 | RTI Health Solutions | Nonprofit | United States | 2 |
| 4 | GlaxoSmithKline Research & Development Limited (United Kingdom) | Company | United Kingdom | 2 |
| 5 | Harbin University of Science and Technology | University | China | 1 |
| 6 | Obuda University | University | Hungary | 1 |
| 7 | University of Technology Sydney | University | Australia | 1 |
| 8 | Higher Colleges of Technology | University | United Arab Emirates | 1 |
| 9 | University of Science and Technology of China | University | China | 1 |
What its papers cite#
| # | Institution | Kind | Country | Links |
|---|---|---|---|---|
| 1 | GlaxoSmithKline (Belgium) | Company | Belgium | 3 |
| 2 | GlaxoSmithKline (United States) | Company | United States | 2 |
| 3 | RTI Health Solutions | Nonprofit | United States | 2 |
| 4 | GlaxoSmithKline Research & Development Limited (United Kingdom) | Company | United Kingdom | 2 |
| 5 | University of Bahrain | University | Bahrain | 1 |
| 6 | Tunis University | University | Tunisia | 1 |
| 7 | Tongji University | University | China | 1 |
| 8 | École Supérieure des Sciences Économiques et Commerciales | Other | France | 1 |
| 9 | Birmingham City University | University | United Kingdom | 1 |
In OpenAlex#
| Item | Value |
|---|---|
| Type | Company |
| Location | London, England, United Kingdom |
| Also known as | GSK |
| Units listed in OpenAlex | 22 |
| Works in OpenAlex | 18,242 |
| Citations | 2,910,452 |
| h-index | 609 |
| i10-index | 29,934 |
| 2-year mean citedness | 5.68 |
| Website | uk.gsk.com |
| ROR | ror.org/01xsqw823 |
| OpenAlex | openalex.org/I188950975 |
| # | Topic | Field | Works |
|---|---|---|---|
| 1 | Asthma and respiratory diseases | Medicine | 2,164 |
| 2 | Chronic Obstructive Pulmonary Disease (COPD) Research | Medicine | 1,891 |
| 3 | Inhalation and Respiratory Drug Delivery | Medicine | 902 |
| 4 | Computational Drug Discovery Methods | Computer Science | 748 |
| 5 | Statistical Methods in Clinical Trials | Mathematics | 660 |
| Year | Works in OpenAlex | Citations received | In the tracked journals | Share |
|---|---|---|---|---|
| 2026 (so far) | 503 | 48,395 | 1 | 0.2% |
| 2025 | 658 | 62,250 | 7 | 1.1% |
| 2024 | 725 | 65,449 | 3 | 0.4% |
| 2023 | 672 | 61,974 | 3 | 0.4% |
| 2022 | 785 | 62,917 | 1 | 0.1% |
| 2021 | 755 | 66,293 | 1 | 0.1% |
| 2020 | 789 | 62,897 | 0 | 0.0% |
| 2019 | 683 | 54,277 | 2 | 0.3% |
| 2018 | 815 | 50,518 | 1 | 0.1% |
| 2017 | 635 | 49,267 | 5 | 0.8% |
Cite this page
Scholar4AI. (2026). GlaxoSmithKline (United Kingdom). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/glaxosmithkline-united-kingdom
@misc{scholar4ai-companies-glaxosmithkline-united-kingdom,
author = {{Scholar4AI}},
title = {GlaxoSmithKline (United Kingdom)},
year = {2026},
howpublished = {\url{https://scholar4ai.com/companies/glaxosmithkline-united-kingdom}},
urldate = {2026-11-05},
note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}